Evidence map›Paper›PMID 22922884›Full record

ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2012

PRKAR1A overexpression is associated with increased ECPKA autoantibody in liver fluke-associated cholangiocarcinoma: application for assessment of the risk group.

Watcharin Loilome, Sasithorn Yooyuen, Nisana Namwat, Paiboon Sithithaworn, Anucha Puapairoj, Junko Kano, Masayuki Noguchi, Masanao Miwa, Puangrat Yongvanit

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Pathogens (Basel, Switzerland) · 2023
    Review
  4. Article
  5. Article
  6. Genetic and environmental determinants of risk for cholangiocarcinoma in Thailand.World journal of gastrointestinal pathophysiology · 2014
    Review
  7. Article
  8. Oxidized alpha-1 antitrypsin as a predictive risk marker of opisthorchiasis-associated cholangiocarcinoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Watcharin LoilomeDepartment of Biochemistry and Liver Fluke and Cholangiocarcinoma Research Center, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand.
Sasithorn Yooyuen
Nisana Namwat
Paiboon Sithithaworn
Anucha Puapairoj
Junko Kano
Masayuki Noguchi
Masanao Miwa
Puangrat Yongvanit
Khon Kaen University · THUniversity of Tsukuba · JPNagahama Institute of Bio-Science and Technology · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cholangiocarcinoma (CCA) associated with Opisthorchis viverrini (Ov) chronic infection is the most frequent primary liver cancer in Thailand, and current approaches to early diagnosis and curative treatments are largely disappointing. We hypothesize a role for protein kinase A (PKA) in Ov-induced CCA. First, we studied the PKA isozyme switching in the liver from the hamster CCA model using quantitative (q) PCR, in situ hybridization, and immunohistochemical and western blot analysis. Second, the presence of extracellular PKA (ECPKA) in CCA cell lines and their conditioned media was demonstrated by western blot and PKA activity assay. Third, we determined the association between PRKAR1A expression and serum ECPKA autoantibody in patients with CCA by ELISA. We demonstrated that an increased PRKAR1A expression is restricted to the biliary cells starting from week 1, with remarkable up-regulation when CCA has completely developed by week 24. The switching of the PKA regulatory subunit isoforms from PRKAR2B/PKAII to PRKAR1A/PKAI is significantly associated with cholangiocyte proliferation. Further, we observed that human CCA cell lines express PRKAR1A but not PRKAR2B and excrete ECPKA. Finally, ECPKA autoantibodies are detected in serum of patients with CCA, adenocarcinoma, and Ov infection with periductal fibrosis, but not from Ov-infected subjects without periductal fibrosis lesion and healthy controls. We conclude that PKA isozyme switching and the PRKAR1A/PKAI pathway might contribute to the induction of cholangiocyte transformation and proliferation in Ov-induced CCA. Overexpression of PRKAR1A leads to secretion of ECPKA which is associated with serum autoantibody that may constitute a biomarker for human CCA genesis.

Indexed as

AdenocarcinomaAnimalsAutoantibodiesBile Duct NeoplasmsBile Ducts, IntrahepaticBlotting, WesternCase-Control StudiesCholangiocarcinomaCricetinaeCulture Media, ConditionedCyclic AMP-Dependent Protein Kinase RIalpha SubunitCyclic AMP-Dependent Protein Kinase RIIbeta SubunitCyclic AMP-Dependent Protein KinasesEnzyme-Linked Immunosorbent AssayFasciola hepaticaFascioliasisAutoantibodiesCulture Media, ConditionedCyclic AMP-Dependent Protein Kinase RIalpha SubunitCyclic AMP-Dependent Protein Kinase RIIbeta SubunitCyclic AMP-Dependent Protein KinasesPRKAR1A protein, humanPRKAR2B protein, humanRNA, Messenger

Identifiers

PMID22922884
OpenAlexW2013187066

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.